Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Wien,
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Wien,
Click here to add this to my saved trials
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Comparison of F-18 FDG PET CT and PET MRI With C-11 Acetate PET CT and PET MRI in the Diagnosis of Active Multiple Myeloma Disease: a Pilot Study
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Comparison of F-18 FDG PET CT and PET MRI With C-11 Acetate PET CT and PET MRI in the Diagnosis of Active Multiple Myeloma Disease: a Pilot Study
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of California Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Indiana Hemophilia and Thrombosis Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Mississippi Center for Advanced Medicine
mi
from
Madison, MS
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Mississippi Center for Advanced Medicine
mi
from
Madison, MS
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Hemophilia Center of Western PA
mi
from
Pittsburgh, PA
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Hemophilia Center of Western PA
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Michigan State University
mi
from
East Lansing, MI
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated:  12/31/1969
Nara Medical University Hospital
mi
from
Kashihara-Shi,
A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A
Status: Enrolling
Updated: 12/31/1969
Nara Medical University Hospital
mi
from
Kashihara-Shi,
Click here to add this to my saved trials
Multiparametric Imaging in Multiple Myeloma
Multiparametric Imaging in Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Multiparametric Imaging in Multiple Myeloma
Multiparametric Imaging in Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
mi
from
Duarte, CA
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
mi
from
Duarte, CA
Click here to add this to my saved trials
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated:  12/31/1969
Clinical Site
mi
from
Los Angeles, CA
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated: 12/31/1969
Clinical Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
mi
from
Baltimore, MD
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
mi
from
Detroit, MI
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
mi
from
Detroit, MI
Click here to add this to my saved trials
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated:  12/31/1969
Clinical Trial Site
mi
from
Bronx, NY
ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab
Status: Enrolling
Updated: 12/31/1969
Clinical Trial Site
mi
from
Bronx, NY
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
San Diego Clinical Trials
mi
from
San Diego, CA
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
San Diego Clinical Trials
mi
from
San Diego, CA
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Adult & Pediatrics Urology
mi
from
Omaha, NE
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Adult & Pediatrics Urology
mi
from
Omaha, NE
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Albany Medical College
mi
from
Albany, NY
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Albany Medical College
mi
from
Albany, NY
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Wake Forest School of Medicine
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
University of Vermont
mi
from
Burlington, VT
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Virginia Urology
mi
from
Richmond, VA
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Virginia Urology
mi
from
Richmond, VA
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
Urology of Virginia, PLLC
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
University of British Columbia
mi
from
Vancouver,
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
University of British Columbia
mi
from
Vancouver,
Click here to add this to my saved trials
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated:  12/31/1969
University of Southern California, Institute of Urology
mi
from
Los Angeles, CA
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II
Status: Enrolling
Updated: 12/31/1969
University of Southern California, Institute of Urology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Nashville, TN
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Brest,
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Brest,
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated:  12/31/1969
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
Status: Enrolling
Updated: 12/31/1969
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Valhalla, NY
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Valhalla, NY
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Greenville, SC
Click here to add this to my saved trials
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated:  12/31/1969
mi
from
Vienna,
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)
Status: Enrolling
Updated: 12/31/1969
mi
from
Vienna,
Click here to add this to my saved trials
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 12/31/1969
Royal Prince Alfred Hospital
mi
from
Camperdown,
Click here to add this to my saved trials
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
A Phase 4, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial of a Single Shot of Intrathecal Ziconotide for the Treatment of Chronic, Medically Refractory Pain From Painful Peripheral Neuropathy or Myelopathy
Status: Enrolling
Updated:  12/31/1969
Ohio State University Department of Neurology
mi
from
Columbus, OH
Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy
A Phase 4, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial of a Single Shot of Intrathecal Ziconotide for the Treatment of Chronic, Medically Refractory Pain From Painful Peripheral Neuropathy or Myelopathy
Status: Enrolling
Updated: 12/31/1969
Ohio State University Department of Neurology
mi
from
Columbus, OH
Click here to add this to my saved trials